Heron Therapeutics announces initiation of phase II clinical study of Cinvanti for the treatment of COVID-19.
Heron Therapeutics announced the initiation of the GUARDS-1 Study, a Phase II clinical study evaluating Cinvanti (aprepitant) injectable emulsion in early hospitalized patients with Coronavirus Disease 2019 (COVID-19)…. read more.